[go: up one dir, main page]

TN2011000349A1 - Sgc stimulators of sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction - Google Patents

Sgc stimulators of sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction

Info

Publication number
TN2011000349A1
TN2011000349A1 TN2011000349A TN2011000349A TN2011000349A1 TN 2011000349 A1 TN2011000349 A1 TN 2011000349A1 TN 2011000349 A TN2011000349 A TN 2011000349A TN 2011000349 A TN2011000349 A TN 2011000349A TN 2011000349 A1 TN2011000349 A1 TN 2011000349A1
Authority
TN
Tunisia
Prior art keywords
sgc
treatment
combination
pde5 inhibitors
activators
Prior art date
Application number
TN2011000349A
Other languages
English (en)
Inventor
Peter Sandner
Jphannes-Peter Stasch
Michael Friedrich Bottcher
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of TN2011000349A1 publication Critical patent/TN2011000349A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TN2011000349A 2009-01-17 2011-07-14 Sgc stimulators of sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction TN2011000349A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09000619 2009-01-17
EP09002177 2009-02-17
PCT/EP2010/000029 WO2010081647A2 (fr) 2009-01-17 2010-01-07 Stimulateurs sgc d'activateurs sgc en combinaison avec des inhibiteurs pde5 dans le traitement du dysfonctionnement érectile

Publications (1)

Publication Number Publication Date
TN2011000349A1 true TN2011000349A1 (en) 2013-03-27

Family

ID=42153923

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000349A TN2011000349A1 (en) 2009-01-17 2011-07-14 Sgc stimulators of sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction

Country Status (20)

Country Link
US (2) US20120022028A1 (fr)
EP (1) EP2387404B1 (fr)
JP (1) JP5780430B2 (fr)
KR (1) KR20110117655A (fr)
CN (1) CN102316870A (fr)
AU (1) AU2010205931A1 (fr)
BR (1) BRPI1006869A2 (fr)
CA (1) CA2749730C (fr)
CL (1) CL2011001712A1 (fr)
EA (1) EA201170942A1 (fr)
ES (1) ES2493718T3 (fr)
IL (1) IL213857A0 (fr)
MA (1) MA32967B1 (fr)
MX (1) MX2011007515A (fr)
SG (1) SG172841A1 (fr)
SV (1) SV2011003973A (fr)
TN (1) TN2011000349A1 (fr)
TW (1) TW201036971A (fr)
WO (1) WO2010081647A2 (fr)
ZA (1) ZA201105085B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095553A1 (fr) * 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Stimulateurs de sgc ou activateurs de sgc en combinaison avec des inhibiteurs de pde5 pour le traitement du dysfonctionnement érectile
ES2549979T3 (es) 2010-05-26 2015-11-03 Adverio Pharma Gmbh El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
WO2011161099A1 (fr) * 2010-06-25 2011-12-29 Bayer Pharma Aktiengesellschaft Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins
WO2012122340A1 (fr) 2011-03-10 2012-09-13 Boehringer Ingelheim International Gmbh Activateurs de guanylate cyclase solubles
WO2013025425A1 (fr) 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Activateurs de guanylate cyclase soluble
WO2013085276A1 (fr) * 2011-12-08 2013-06-13 에스케이케미칼 주식회사 Film pour administration orale contenant du mirodénafil ou l'un de ses sels pharmaceutiquement acceptables
US8906904B2 (en) * 2012-09-07 2014-12-09 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
WO2015089105A1 (fr) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
SG11201700507XA (en) 2014-07-22 2017-02-27 Boehringer Ingelheim Int Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
ES2912648T3 (es) 2015-11-16 2022-05-26 Topadur Pharma Ag Derivados de 2-fenil-3,4-dihidropirrolo[2,1-f] [1,2,4]triazinona como inhibidores de la fosfodiesterasa y usos de los mismos
US11155558B2 (en) 2017-05-22 2021-10-26 Topadur Pharma Ag Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
IL282618B2 (en) 2018-11-28 2025-05-01 Topadur Pharma Ag Novel dual-action soluble guanylate cyclase activators and phosphodiesterase inhibitors and their uses
CN110305837A (zh) * 2019-06-05 2019-10-08 西北师范大学 磷酸二酯酶5活性抑制剂作为诱导斑马鱼卵母细胞成熟的催熟剂的应用
WO2021245192A1 (fr) 2020-06-04 2021-12-09 Topadur Pharma Ag Nouveaux activateurs de la guanylate cyclase soluble à double mode d'action et inhibiteurs de phosphodiestérase et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB371800A (en) 1929-10-21 1932-04-28 Willem Zaadnoordijk A process of filtering gases and fogs
GB369003A (en) 1931-03-25 1932-03-17 Richard Henry Sansome Improvements in fire extinguishing fluids
KR100720844B1 (ko) * 1998-07-08 2007-05-25 사노피-아벤티스 도이칠란트 게엠베하 황 치환된 설포닐아미노카복실산 ｎ-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20100144864A1 (en) * 2007-04-05 2010-06-10 Ironwood Pharmaceuticals, Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
AU2008250643A1 (en) * 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC stimulators, sGC activators and combinations for the treatment of urological disorders

Also Published As

Publication number Publication date
EP2387404A2 (fr) 2011-11-23
ES2493718T3 (es) 2014-09-12
US20140288079A1 (en) 2014-09-25
CA2749730A1 (fr) 2010-07-22
TW201036971A (en) 2010-10-16
ZA201105085B (en) 2012-09-26
EA201170942A1 (ru) 2012-02-28
AU2010205931A1 (en) 2011-07-28
EP2387404B1 (fr) 2014-06-25
CA2749730C (fr) 2017-02-14
CN102316870A (zh) 2012-01-11
IL213857A0 (en) 2011-07-31
SV2011003973A (es) 2011-12-06
JP2012515176A (ja) 2012-07-05
SG172841A1 (en) 2011-08-29
BRPI1006869A2 (pt) 2016-03-15
WO2010081647A3 (fr) 2010-10-21
KR20110117655A (ko) 2011-10-27
MX2011007515A (es) 2011-08-12
CL2011001712A1 (es) 2012-04-09
JP5780430B2 (ja) 2015-09-16
WO2010081647A2 (fr) 2010-07-22
US20120022028A1 (en) 2012-01-26
MA32967B1 (fr) 2012-01-02

Similar Documents

Publication Publication Date Title
TN2011000349A1 (en) Sgc stimulators of sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction
MY159697A (en) Sgc stimulators or sgc activators alone and in combination with pde5 inhibitors for the treatment of cystic fibrosis
TN2012000550A1 (en) THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).
WO2012064667A3 (fr) Traitement d'addiction et de troubles de contrôle des impulsions au moyen d'inhibiteurs de la pde7
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
IN2012DN01869A (fr)
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
WO2011156405A3 (fr) Formulations pour pulvérisation orale et méthodes d'administration de sildenafil
CL2012001329A1 (es) Procedimiento de purificacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo-[3,4-b]piridin-3-il] pirimidin-5-il} metilcarbamato de metilo; y el compuesto intermediario que se obtiene.
MX2009004696A (es) Uso de 3-alfa-androestandiol, opcionalmente en combinacion con un inhibidor pde5, en el tratamiento de disfuncion sexual.
MY157218A (en) Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
PH12012500773A1 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2014027981A3 (fr) Formulations de comprimés effervescents de dapoxétine et d'un inhibiteur de pde5
CA2677690A1 (fr) Traitement destine a une ejaculation precoce et aux troubles de l'erection comorbides
WO2013176877A3 (fr) Traitement de la dépendance et des troubles du contrôle des impulsions à l'aide d'inhibiteurs de pde7
UA105940C2 (uk) Лікарська комбінація з теоброміном та опіатом і її використання в лікуванні кашлю
PH12012501203A1 (en) Combination of theobromine with a decongestant and its use for the treatment of cough
TW200942540A (en) Novel salt
MX2016002581A (es) Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5.
TN2011000038A1 (en) Nitrogenated derivatives of pancratistatin
PH22012000077U1 (en) A new pharmaceutical preparation for the cure of baldness